Prospective data acquisition of diagnosis, treatment and course of disease in adult acute lymphoblastic leukemia (ALL) and related diseases in conjunction with a prospective collection of biomaterial
Recruiting
- Conditions
- C91.0Acute lymphoblastic leukaemia [ALL]
- Registration Number
- DRKS00003929
- Lead Sponsor
- GMALL-Studiengruppe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
# Age min . 18 years
# Written informed consent
# Therapy analogous to a GMALL therapy optimization study or GMALL therapy recommendation
# One of the following three inclusion criteria :
# 1 acute lymphoblastic leukemia
# 2 other leukemias (NK-cell lymphoma / leukemia or acute biphenotypic leukemia)
# 3. Non-Hodgkin's lymphoma following subtypes ( WHO classification ) : Burkitt 's lymphoma (incl. Atypical Burkitt 's lymphoma, Burkitt-like lymphoma ) , diffuse large B-cell lymphoma ( DLBCL particular primary mediastinal , DLBCL with Burkitt -Signature , C-myc-positive DLBCL ), B-cell lymphoblastic lymphoma, T-cell lymphoblastic lymphoma, Large Cell Anaplastic lymphoma, NHL Other
Exclusion Criteria
non
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method # Collection of input features and prognostic factors ( including newer methods, such as MRD determination at different times )<br># Survey of disease status and selected therapies<br># Survey of therapy procedure included the overall and disease-free survival, response rate and duration of the various therapies and patient subgroups<br>
- Secondary Outcome Measures
Name Time Method # Collect data on treatment with newer forms of therapy ( eg molecular therapies ) and use of modern supportive medications ( eg PEG - G - CSF , palifermin )<br># Collection of therapy and late effects<br># Survey of quality of diagnosis and treatment of A